Julian Pineau
throws in on censorship. (For those unfamiliar, he is a respected coach who studies the interplay of training, diet, and the nervous system.)
Outside the US, there are
64 registered clinical trials concerning the drug. 22 have completed and 33 are recruiting. Within the US,
zero have started. One was supposed to complete by December, but it was cancelled. (Perhaps Dr. Isenberg and Professor Gentile can shed some light.) 5 are recruiting, but they all plan for inadequate sample sizes (approximately 250 each). The
Duke study seeks to enroll 15,000 participants. However, it was supposed to start this month, but hasn't even started enrolling, so it is likely cancelled. This paucity of research is rather peculiar for a nation which accounts for $80B / $180B of worldwide pharmaceutical R&D spending.